Evidence map›Paper›PMID 30281213›Full record

ArticlePigment cell & melanoma research2018

Frontiers in pigment cell and melanoma research.

Fabian V Filipp, Stanca Birlea, Marcus W Bosenberg, Douglas Brash, Pamela B Cassidy, Suzie Chen, John A D'Orazio, Mayumi Fujita, Boon-Kee Goh, Meenhard Herlyn and 17 more

Abstract read
In one paragraph

Article in Pigment cell & melanoma research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. The triennial International Pigment Cell Conference (IPCC).Journal of translational medicine · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Fabian V FilippSystems Biology and Cancer Metabolism, Program for Quantitative Systems Biology, University of California Merced, Merced, California.ORCID 0000-0001-9889-5727
Stanca BirleaDepartment of Dermatology, University of Colorado Denver, Aurora, Colorado.
Marcus W BosenbergDepartment of Dermatology and Dermatopathology, Yale School of Medicine, New Haven, Connecticut.
Douglas BrashDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut.
Pamela B CassidyDepartment of Dermatology, Oregon Health and Science University, Portland, Oregon.
Suzie ChenSusan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey.
John A D'OrazioMarkey Cancer Center, University of Kentucky College of Medicine, Lexington, Kentucky.
Mayumi FujitaDepartment of Dermatology, University of Colorado Denver, Aurora, Colorado.
Boon-Kee GohMount Elizabeth Medical Centre, Skin Physicians Private Limited, Singapore, Singapore.
Meenhard HerlynDepartment of Molecular and Cellular Oncogenesis, Wistar Institute, Philadelphia, Pennsylvania.
Arup K IndraDepartment of Dermatology, Oregon Health and Science University, Portland, Oregon.
Lionel LarueEquipe Labellisée Ligue Contre le Cancer, Normal and Pathological Development of Melanocytes, UMR 3347, CNRS, Institut Curie, Orsay, France.
Sancy A LeachmanDepartment of Dermatology, Oregon Health and Science University, Portland, Oregon.
Caroline Le PooleLurie Comprehensive Cancer Center, Northwestern University at Chicago, Chicago, Illinois.
Feng Liu-SmithChao Family Comprehensive Cancer Center, University of California Irvine, Orange, California.
Prashiela MangaRonald O Perlman Department of Dermatology, New York University Langone Medical Center, New York, New York.
Lluis MontoliuCNB-CSIC, CIBERER-ISCIII, Campus de Cantoblanco, Centro Nacional de Biotecnología, Madrid, Spain.
David A NorrisDepartment of Dermatology, University of Colorado Denver, Aurora, Colorado.
Yiqun ShellmanDepartment of Dermatology, University of Colorado Denver, Aurora, Colorado.
Keiran S M SmalleyDepartment of Tumor Biology, Moffitt Cancer Center, Tampa, Florida.
Richard A SpritzHuman Medical Genetics and Genomics Program, University of Colorado Denver, Aurora, Colorado.
Richard A SturmDermatology Research Centre, University of Queensland Diamantina Institute, University of Queensland, Brisbane, Queensland, Australia.
Susan M SwetterDepartment of Dermatology, Stanford University, Palo Alto, California.
Tamara TerzianDepartment of Dermatology, University of Colorado Denver, Aurora, Colorado.
Kazumasa WakamatsuDepartment of Chemistry, Fujita Health University School of Health Sciences, Toyoake, Japan.
Jeffrey S WeberLaura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York.
Neil F BoxDepartment of Dermatology, University of Colorado Denver, Aurora, Colorado.

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI PAUL M. LIEBERMAN · 1985 to 2026
$75.9M
Tumor pyruvate kinase as key regulator of cancer metabolismR00CA154887 · NCI · UNIVERSITY OF CALIFORNIA, MERCED · PI FILIPP, FABIAN VOLKER · 2012 to 2014
$725k
Targeting p53-Dependent Repigmentation in VitiligoK01AR063203 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI TERZIAN, TAMARA G · 2012 to 2016
$503k
p53 in MelanomagenesisR03CA191937 · NCI · UNIVERSITY OF COLORADO DENVER · PI TERZIAN, TAMARA G · 2016 to 2017
$156k
2017 (IPCC) International Pigment Cell ConferenceR13AR071775 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI NORRIS, DAVID A. · 2017 to 2017
$15k
NCI NIH HHS P30 CA010815NCI NIH HHS R00 CA154887NCI NIH HHS R03 CA191937NIAMS NIH HHS K01 AR063203NIAMS NIH HHS R13 AR071775
6 · The paper itself

Abstract

In this perspective, we identify emerging frontiers in clinical and basic research of melanocyte biology and its associated biomedical disciplines. We describe challenges and opportunities in clinical and basic research of normal and diseased melanocytes that impact current approaches to research in melanoma and the dermatological sciences. We focus on four themes: (1) clinical melanoma research, (2) basic melanoma research, (3) clinical dermatology, and (4) basic pigment cell research, with the goal of outlining current highlights, challenges, and frontiers associated with pigmentation and melanocyte biology. Significantly, this document encapsulates important advances in melanocyte and melanoma research including emerging frontiers in melanoma immunotherapy, medical and surgical oncology, dermatology, vitiligo, albinism, genomics and systems biology, epidemiology, pigment biophysics and chemistry, and evolution.

Indexed as

Biomedical ResearchAnimalsDisease Models, AnimalDrug Resistance, NeoplasmHumansMelanocytesMelanomaPigmentationalbinismcancer preventiondermatologyimmunotherapyInternational Pigment Cell ConferencemelaninmelanocytemelanomamelasmapigmentationskinUVvitiligo

Identifiers

PMID30281213
PMCPMC6701837

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.